Latest Insider Transactions at Graybug Vision, Inc. (GRAY)
This section provides a real-time view of insider transactions for Graybug Vision, Inc. (GRAY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of GRAYBUG VISION, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of GRAYBUG VISION, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 02
2023
|
A. Rachel Leheny CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
1,000
+14.29%
|
$4,000
$4.8 P/Share
|
|
Jun 02
2023
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Direct |
1,687
+12.16%
|
$6,748
$4.9 P/Share
|
|
Jun 01
2023
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Direct |
2,000
+16.0%
|
$8,000
$4.42 P/Share
|
|
May 31
2023
|
Eric Bjerkholt |
BUY
Open market or private purchase
|
Direct |
250
+3.33%
|
$1,000
$4.15 P/Share
|
|
May 31
2023
|
A. Rachel Leheny CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
1,000
+16.67%
|
$4,000
$4.21 P/Share
|
|
May 30
2023
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Indirect |
2,000
+20.0%
|
$6,000
$3.86 P/Share
|
|
May 30
2023
|
Eric Bjerkholt |
BUY
Open market or private purchase
|
Direct |
5
+0.15%
|
$15
$3.25 P/Share
|
|
May 23
2023
|
A. Rachel Leheny CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
3,000
+42.86%
|
$9,000
$3.34 P/Share
|
|
May 23
2023
|
Eric Bjerkholt |
BUY
Open market or private purchase
|
Direct |
500
+12.73%
|
$1,500
$3.27 P/Share
|
|
May 23
2023
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Direct |
2,000
+19.05%
|
$6,000
$3.26 P/Share
|
|
May 22
2023
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Indirect |
6,000
+50.0%
|
$12,000
$2.95 P/Share
|
|
May 19
2023
|
Eric Bjerkholt |
BUY
Open market or private purchase
|
Direct |
199
+6.36%
|
$398
$2.65 P/Share
|
|
May 19
2023
|
Fred A Middleton |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$20,000
$2.85 P/Share
|
|
May 18
2023
|
Eric Bjerkholt |
BUY
Open market or private purchase
|
Direct |
301
+4.97%
|
$602
$2.68 P/Share
|
|
May 17
2023
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Direct |
3,000
+31.58%
|
$6,000
$2.68 P/Share
|
|
May 17
2023
|
Eric Bjerkholt |
BUY
Open market or private purchase
|
Direct |
200
+7.61%
|
$400
$2.67 P/Share
|
|
May 16
2023
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Indirect |
1,800
+50.0%
|
$3,600
$2.72 P/Share
|
|
May 16
2023
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Direct |
3,500
+50.0%
|
$7,000
$2.71 P/Share
|
|
May 16
2023
|
Sudarshan Hebbar Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$20,000
$2.7 P/Share
|
|
May 16
2023
|
Eric Bjerkholt |
BUY
Open market or private purchase
|
Direct |
800
+26.41%
|
$1,600
$2.7 P/Share
|
|
May 16
2023
|
A. Rachel Leheny CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$2,000
$2.69 P/Share
|
|
Mar 23
2023
|
Christina Ackermann Director |
BUY
Sale (or disposition) back to the issuer
|
Direct |
1,429
+50.0%
|
-
|
|
Mar 23
2023
|
Eric Bjerkholt |
BUY
Sale (or disposition) back to the issuer
|
Direct |
1,429
+50.0%
|
-
|
|
Mar 23
2023
|
Robert S Breuil Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,677
-26.41%
|
$63,385
$5.5 P/Share
|
|
Mar 23
2023
|
Robert S Breuil Chief Financial Officer |
BUY
Sale (or disposition) back to the issuer
|
Direct |
36,657
+43.3%
|
-
|
|
Mar 23
2023
|
Julia Marie Eastland Director |
BUY
Sale (or disposition) back to the issuer
|
Direct |
1,429
+50.0%
|
-
|
|
Mar 23
2023
|
Frederic Guerard |
SELL
Payment of exercise price or tax liability
|
Direct |
20,383
-18.34%
|
$101,915
$5.5 P/Share
|
|
Mar 23
2023
|
Frederic Guerard |
BUY
Sale (or disposition) back to the issuer
|
Direct |
83,705
+42.97%
|
-
|
|
Mar 23
2023
|
Dirk Sauer Director |
BUY
Sale (or disposition) back to the issuer
|
Direct |
1,429
+50.0%
|
-
|
|
Mar 23
2023
|
Christy L Shaffer Director |
BUY
Sale (or disposition) back to the issuer
|
Direct |
1,429
+50.0%
|
-
|
|
Mar 23
2023
|
Parisa Zamiri Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,901
-38.18%
|
$89,505
$5.5 P/Share
|
|
Mar 23
2023
|
Parisa Zamiri Chief Medical Officer |
BUY
Sale (or disposition) back to the issuer
|
Direct |
42,771
+47.71%
|
-
|
|
Mar 20
2023
|
Sanderling Venture Partners Vi LP |
BUY
Grant, award, or other acquisition
|
Indirect |
936,656
+50.0%
|
-
|
|
Mar 20
2023
|
Sanderling Venture Partners Vi LP |
BUY
Grant, award, or other acquisition
|
Direct |
703,388
+50.0%
|
-
|
|
Mar 20
2023
|
Valence Investments Spv Iv LLC > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
382,337
+50.0%
|
-
|
|
Mar 20
2023
|
Valence Investments Spv Iv LLC > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
356,989
+50.0%
|
-
|
|
Mar 20
2023
|
Fred A Middleton |
BUY
Grant, award, or other acquisition
|
Indirect |
1,648,220
+50.0%
|
-
|
|
Mar 20
2023
|
Kenneth A. Stauderman Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,944
+50.0%
|
-
|
|
Mar 20
2023
|
Eric W Roberts CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Indirect |
749,987
+50.0%
|
-
|
|
Mar 20
2023
|
Robert N Wilson |
BUY
Grant, award, or other acquisition
|
Direct |
181,655
+50.0%
|
-
|
|
Mar 20
2023
|
A. Rachel Leheny CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Indirect |
739,326
+50.0%
|
-
|
|
Mar 14
2023
|
Robert S Breuil Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,730
-1.06%
|
$0
$0.58 P/Share
|
|
Mar 14
2023
|
Robert S Breuil Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.96%
|
-
|
|
Mar 03
2023
|
Parisa Zamiri Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
42,894
-24.07%
|
$0
$0.57 P/Share
|
|
Mar 03
2023
|
Parisa Zamiri Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
120,655
+40.37%
|
-
|
|
Mar 03
2023
|
Frederic Guerard |
SELL
Payment of exercise price or tax liability
|
Direct |
89,344
-18.89%
|
$0
$0.57 P/Share
|
|
Mar 03
2023
|
Frederic Guerard |
BUY
Exercise of conversion of derivative security
|
Direct |
315,496
+40.01%
|
-
|
|
Mar 03
2023
|
Robert S Breuil Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
49,434
-23.73%
|
$0
$0.57 P/Share
|
|
Mar 03
2023
|
Robert S Breuil Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
121,217
+36.79%
|
-
|
|
Dec 12
2022
|
Robert S Breuil Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,729
-1.95%
|
$0
$0.58 P/Share
|